Chapter I. Diabetic Peripheral Neuropathy

Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015

Nikolaos Papanas¹, Dan Ziegler^2,3

Manuscript submitted April 14, 2015; resubmitted April 27, 2015; accepted May 7, 2015.

Keywords: diabetes, diabetic neuropathy, hyperglycemia, prevalence, prediabetes, risk factors, hypertension

Abstract

Distal symmetric sensorimotor polyneuropathy (DSPN) is the most common neurological manifestation in diabetes. Major risk factors of DSPN include diabetes duration, hyperglycemia, and age, followed by prediabetes, hypertension, dyslipidemia, and obesity. Height, smoking, insulin resistance, hypoinsulinemia, and others represent an additional risk. Importantly, hyperglycemia, hypertension, dyslipidemia, obesity, and smoking are modifiable. Stringent glycemic control has been shown to be effective in type 1, but not to the same extent in type 2 diabetes. Antilipidemic treatment, especially with fenofibrate, and multi-factorial intervention have produced encouraging results, but more experience is necessary. The major comorbidities of DSPN are depression, autonomic neuropathy, peripheral arterial disease, cardiovascular disease, nephropathy, retinopathy, and medial arterial calcification. Knowledge of risk factors and comorbidities has the potential to enrich the therapeutic strategy in clinical practice as part of the overall medical care for patients with neuropathy. This article provides an updated overview of DSPN risk factors and comorbidities.

Fulltext: HTML , PDF (195KB)

This article has been cited by other articles:

	Prevalence of Peripheral Neuropathy and associated factors in HIV-infected patients Benevides ML, Filho SB, Debona R, Bergamaschi EN, Nunes JC J Neurol Sci 2017. 375:316-320
	The period effect in the prevalence of proliferative diabetic retinopathy, gross proteinuria, and peripheral neuropathy in type 1 diabetes: A longitudinal cohort study Kiire CA, Horak K, Lee KE, Klein BE, Klein R Plos One 2017. 12(3):e0174979
	Factors associated with peripheral neuropathy in type 2 diabetes: Subclinical versus confirmed neuropathy Unmar Y, Zafar MI, Gao F J Huazhong Univ Sci Technolog Med Sci 2017. 37(3):337-342
	Arterial Calcification in Diabetes Mellitus: Preclinical Models and Translational Implications Stabley JN, Towler DA Arterioscler Thromb Vasc Biol 2017. 37(2):205-217
	Why Not to Use the Handgrip Test in the Assessment of Cardiovascular Autonomic Neuropathy Among Patients with Diabetes Mellitus? Körei AE, Kempler M, Istenes I, Vagi OE, Putz Z, Horvath VJ, Keresztes K, Lengyel C, Tabak AG, Spallone V, Kempler P Curr Vasc Pharmacol 2017. 15(1):66-73
	NC-stat for the diagnosis of diabetic polyneuropathy Pafili K, Maltezos E, Papanas N Expert Rev Med Devices 2017. 17:1-4
	Comparison of efficacy between traditional Chinese medicine combined with western medicine and simple western medicine for patients with NPDR Rao XJ, Wu YM, Wei LJ, Ma Y Int Eye Sci 2017. In press
	Analysis of the association between glucose profiles and β-cell function for diabetic cardiovascular autonomic neuropathy in China Fang P, Dong J, Zeng F, Tang Z J Diabetes Investig 2016. In press
	Letter to the Editor Regarding: Diabetic Peripheral Neuropathy as a Predictor of Asymptomatic Myocardial Ischemia in Type 2 Diabetes Mellitus: A Cross-Sectional Study Pafili K, Papanas N Adv Ther 2016. 33(10):1848-1852
	Impact of neuropathy on the adherence to diabetes-related self-care activities: a cross-sectional study Timar B, Timar R, Schiller A, Oancea C, Roman D, Vlad M2 Balinisteanu B, Mazilu O Patient Prefer Adherence 2016. 10:1169-1175
	Emerging drugs for diabetic peripheral neuropathy and neuropathic pain Papanas N, Ziegler D Expert Opin Emerg Drugs 2016. 21(4):393-407
	Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ Breast Cancer Res Treat 2016. 159(2):327-333